Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Patients with relapsed/refractory CLL / SLL treated with zanubrutinib had longer remissions than patients treated with ibrutinib.
Fixed-duration glofitamab, a bispecific T-cell engager (BITE) monoclonal antibody, induces durable complete remissions (CR) and has a manageable safety profile in patients with Richter’s transformation.
This should not be part of anyone’s game plan. Still, it was nice to read that for at least this one 67-year-old asymptomatic CLL patient, a case of COVID-19 associated with low blood counts and a broad spectrum of treatments resulted in his CLL becoming undetectable in his bone marrow and blood, and his scans had all returned to normal.
Ask the Doctor Question: I am taking Calquence for CLL. I stopped taking predison last January and started having muscle and leg pain. It’s been six-months and even with exercise it
On March 22, 2018, I was an outpatient at the Seattle Cancer Care Alliance where I was transfused with my own T-cells that had been harvested a few weeks earlier, then
#2 At virtual ASCO 2020, Dr. John Byrd led a group of researchers to report the latest from the first phase 2 study of acalabrutinib, ACE-CL-001 (NCT02029443), a next-generation BTK inhibitor, which is now approved for CLL patients, both treatment-naïve as well as those with relapsed/refractory disease.
It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.
A new clinical trial is testing the combination of venetoclax with obinutuzumab and magrolimab for relapsed / refractory B-cell lymphomas.
Most resistance mutations acquired by CLL patients during zanubrutinib treatment occurred at a single site on BTK.
One click to our most popular content.
